CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced the launch of PrecisionCHD™, an ...

Cardio Diagnostics Holdings will partner with a longtime distribution leader in India and an Indian network of nearly 300 ...

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics, Inc, a biotechnology company making cardiovascular disease prevention and early detection more accessible, personalized and precise, announces the launch ...

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, and Family Medicine Specialists (FMS), a ...

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, today announced the publication of its ...

Investing.com -- Cardio Diagnostics Holdings Inc (NASDAQ:CDIO) stock rose 9.3% in premarket trading Wednesday after the company announced a strategic agreement to launch its PrecisionCHD test in India ...

The final gapfill payment rate for both the Epi+Gen CHD™ and PrecisionCHD™ tests is higher at $854 compared to the preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for ...

Shares of Cardio Diagnostics Holdings Inc (NASDAQ:CDIO) climbed about 9.3% in premarket trading on Wednesday after the company unveiled plans to expand into India, marking its first move beyond the U.

One of the strongest predictors of long-term mortality among patients undergoing a cardiac stress test is the need for a pharmacologic versus treadmill test, new data show. Moreover, although the risk ...